Table 1 Patient characteristics
From: Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
No Reaction | Reaction | ||
|---|---|---|---|
103 | 22 | ||
Female | 100 (97.1%) | 18 (81.8%) | |
Male | 3 (2.91%) | 4 (18.2%) | 0.005** |
Age at first dose of RTX | 37 (16–73) | 30 (18–56) | 0.068 |
Cycles of RTX | 1.91 (1–9) | 2.18 (1–8) | 0.202 |
ANA positive | 90 (87.4%) | 22 (100%) | 0.066 |
dsDNA positive | 65 (63.1%) | 16 (72.7%) | 0.972 |
No ENA pos | 25 (24.3%) | 6 (27.3%) | 0.767 |
1 ENA pos | 26 (25.2%) | 5 (22.7%) | 0.804 |
2 ENA pos | 28 (27.2%) | 8 (36.4%) | 0.388 |
3 ENA pos | 16 (15.5%) | 2 (9.1%) | 0.435 |
4 ENA pos | 8 (7.8%) | 1 (4.5%) | 0.596 |
Anti-Ro positive | 57 (55.3%) | 12 (54.5%) | 0.946 |
Anti-La positive | 24 (23.3%) | 2 (9.1%) | 0.136 |
Anti-Sm positive | 33 (32.0%) | 5 (22.7%) | 0.389 |
Anti-RNP positive | 48 (46.6%) | 12 (54.5%) | 0.498 |
Caucasian | 40 (38.8%) | 9 (40.9%) | 0.856 |
Afro-Caribbean | 43 (41.7%) | 10 (45.5%) | 0.749 |
Asian | 16 (15.5%) | 2 (9.1%) | 0.435 |
Other | 4 (3.9%) | 1 (4.5%) | 0.886 |